Swiss National Bank Buys 38,400 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Swiss National Bank raised its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 94.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 79,100 shares of the company’s stock after buying an additional 38,400 shares during the period. Swiss National Bank owned about 0.15% of Janux Therapeutics worth $4,235,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Victory Capital Management Inc. lifted its stake in shares of Janux Therapeutics by 143.4% during the third quarter. Victory Capital Management Inc. now owns 29,745 shares of the company’s stock valued at $1,351,000 after acquiring an additional 17,525 shares during the period. Intech Investment Management LLC bought a new stake in Janux Therapeutics during the 3rd quarter worth about $368,000. Charles Schwab Investment Management Inc. lifted its position in Janux Therapeutics by 202.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after purchasing an additional 156,675 shares during the period. Algert Global LLC bought a new position in shares of Janux Therapeutics in the 3rd quarter valued at about $1,112,000. Finally, The Manufacturers Life Insurance Company grew its position in shares of Janux Therapeutics by 27.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 30,595 shares of the company’s stock worth $1,390,000 after buying an additional 6,547 shares during the period. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock opened at $30.83 on Wednesday. The company has a market capitalization of $1.82 billion, a P/E ratio of -26.35 and a beta of 3.23. The business has a 50-day moving average of $36.33 and a two-hundred day moving average of $46.31. Janux Therapeutics, Inc. has a 1 year low of $28.92 and a 1 year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Insider Activity

In related news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total value of $140,994.86. Following the sale, the insider now owns 82,139 shares of the company’s stock, valued at approximately $3,473,658.31. This trade represents a 3.90 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. purchased 110,206 shares of Janux Therapeutics stock in a transaction on Friday, March 7th. The shares were purchased at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the transaction, the director now owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. The trade was a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 25,002 shares of company stock worth $1,279,953 over the last quarter. 29.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

JANX has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. Wedbush reissued an “outperform” rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. BTIG Research lifted their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Leerink Partners upped their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $200.00 target price on shares of Janux Therapeutics in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $92.44.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.